NRG Therapeutics

energizing drug discovery in neurodegenerative diseases.

NRG Therapeutics initiates a PET biodistribution trial for its lead clinical asset, **NRG5051**, to study its distribution in the body. The trial aims to support drug development for neurodegenerative diseases by evaluating how the compound behaves in vivo. This step follows earlier preclinical research and marks progress toward potential clinical applications.

Oct 2026nrgtherapeutics.comNews article

NRG Therapeutics presents clinical data for its lead asset, **NRG5051**, demonstrating a novel disease-modifying approach to **amyotrophic lateral sclerosis (ALS)**. The findings suggest potential therapeutic mechanisms distinct from existing treatments. The company focuses on advancing neurodegenerative disease research through innovative drug discovery.

Aug 2026nrgtherapeutics.comNews article

NRG Therapeutics appoints Claus Sundgreen M.D. as its new Chief Medical Officer. The company focuses on advancing drug discovery for neurodegenerative diseases. Sundgreen brings medical leadership to support NRG’s research initiatives in this therapeutic area.

Aug 2026nrgtherapeutics.comNews article

NRG Therapeutics begins dosing the first participants in its first-in-human Phase 1 clinical trial of **NRG5051**, a potential disease-modifying treatment for **amyotrophic lateral sclerosis (ALS), motor neuron disease (MND), and Parkinson’s**. The trial evaluates safety and tolerability in early-stage testing. NRG5051 targets neurodegenerative pathways, marking a key milestone in the company’s pipeline.

Jan 2026nrgtherapeutics.comNews article